Roche's Transfer Of Assets To Arrowhead May Create Most-Comprehensive RNAi Firm
This article was originally published in The Pink Sheet Daily
Executive Summary
After an expensive foray into RNAi, Roche is handing off its substantial portfolio to Arrowhead, in exchange for a 10% stake in the company and right-of-first-negotiation to programs and earn-out potential.